3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Breast
3
Genitourinary
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Leiomyosarcoma
1
Interventions
Doxorubicin
40
Radiotherapy
30
Ifosfamide
28
Vincristine
27
Cyclophosphamide
24
Imatinib Mesylate
20
Etoposide
20
Dactinomycin
14
Radiation
13
Filgrastim
11
Temozolomide
9
Sunitinib
9
Trabectedin
8
Methotrexate
8
Specimen Handling
7
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Chemotherapy, Adjuvant
6
pazopanib
5
nilotinib
5
Zoledronic Acid
5
Neoadjuvant Therapy
5
Irinotecan
5
Cisplatin
5
Carboplatin
5
X-Rays
4
Vinorelbine
4
Topotecan
4
Surgical Procedures, Operative
4
Procarbazine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Tablets
×
Sarcoma
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled